Glaukos Corp (NYSE:GKOS)
$ 127.45 1.18 (0.93%) Market Cap: 7.00 Bil Enterprise Value: 6.83 Bil PE Ratio: 0 PB Ratio: 10.51 GF Score: 64/100

Glaukos Corp at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 01:15AM GMT
Release Date Price: $46.15 (+1.79%)
K. Gong
JPMorgan Chase & Co, Research Division - Associate

Okay. I want to thank everyone for being here in the last session today on Tuesday. My name is Allen Gong. I'm on the medical supplies and devices team here at JPMorgan. I'm really excited to be introducing members of the Glaukos management team and especially Tom Burns, who will be kicking us off with some prepared remarks before we bring on more members for the Q&A. All yours.

Thomas William Burns
Glaukos Corporation - Chairman & CEO

Thank you. Well, good evening, and thank you for joining us this evening, and I'm happy to give you an update on the progress that we're making at Glaukos. From the inception of our business, our mission has been to transform glaucoma therapy, but our aspirations have always been higher.

And so today, we seek to elevate the standard of care across 3 major therapeutic areas, glaucoma, corneal health and retinal disease. Innovation is at the core of everything we do here at Glaukos. And we've taken on this mantra of the company of "We'll Go First".

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot